India's Supreme Court to Determine Competition Commission's Authority Over Patent-Related Antitrust Cases
Key Insights
India's Supreme Court will rule on whether the Competition Commission of India (search) (CCI) has jurisdiction to investigate anti-competitive conduct arising from patent rights exercise, following conflicting tribunal decisions.
The case centers on pharmaceutical company Vifor International AG's patented drug Ferric Carboxymaltose (FCM), where the National Company Law Appellate Tribunal (search) ruled the CCI lacks jurisdiction over patent-related competition disputes.
The Supreme Court has stayed portions of the NCLAT ruling that held the Patents Act, 1970 overrides the Competition Act, 2002 in matters involving patent rights abuse.
India's Supreme Court is set to deliver a landmark ruling on the jurisdictional boundaries between patent law and competition law, following a Monday decision to examine whether the Competition Commission of India (search) (CCI) has authority to investigate anti-competitive conduct arising from patent rights exercise.
A bench of Justices J B Pardiwala and Vijay Bishnoi stayed portions of a National Company Law Appellate Tribunal (search) (NCLAT) ruling that effectively excluded patent-related disputes from the CCI's purview. The NCLAT had held that the Competition Act, 2002 has no application where claims of abuse of dominance are rooted in patent rights use, determining such disputes fall solely within the Patents Act, 1970 framework.
The Vifor International Case
The legal challenge stems from a complaint against Swiss pharmaceutical firm Vifor International AG concerning its patented drug Ferric Carboxymaltose (FCM). While the CCI had initially dismissed the complaint on merits in 2022, the NCLAT went further by ruling the regulator lacked jurisdiction altogether, reasoning that the Patents Act, being a special statute, overrides the Competition Act in patent-related matters.
The NCLAT supported its decision by citing Section 3(5) of the Competition Act, which safeguards reasonable conditions imposed to protect intellectual property rights. The tribunal also relied on a 2023 Delhi High Court division bench judgment in the Ericsson (search) and Monsanto (search) cases, noting the Supreme Court had previously declined to interfere with that ruling.
Precedent-Setting Cases
The jurisdictional conflict has roots in several high-profile disputes. In the Ericsson (search) matter, mobile handset makers Micromax (search) and Intex (search) approached the CCI alleging excessive royalty demands for standard essential patents. While the CCI ordered a probe after forming a prima facie view, Ericsson successfully challenged the proceedings before the Delhi High Court.
Similarly, in the Monsanto (search) case, seed companies sought CCI examination of allegations that Monsanto engaged in anti-competitive conduct by charging excessive royalties for genetically modified cotton seeds and failing to make patents reasonably available. A Delhi High Court division bench ultimately set aside CCI proceedings in both cases, holding that the Patents Act constitutes a complete code for issues including unreasonable licensing terms, patent rights abuse, and compulsory licensing.
Industry Implications
The pharmaceutical sector is closely monitoring this development, as companies invest heavily in research and development while relying on patent protection to recoup costs and incentivize innovation. The Supreme Court's clarification that its consideration would be confined to jurisdiction questions, not extending to underlying competition dispute merits, provides some procedural clarity while the broader issues remain unresolved.
CSL Limited, Vifor International AG's parent company, reported a Price-to-Earnings ratio of approximately 20.47 as of January 2026, with stock trading around AUD 181.42. The company faces low single-digit revenue growth expectations for fiscal year 2026 and plans to demerge its Seqirus (search) vaccine business.
Regulatory Framework at Stake
The Supreme Court's intervention represents a pivotal moment for India's regulatory framework governing innovation-driven industries. The decision will influence how pharmaceutical companies and other technology-intensive sectors manage patent portfolios and market strategies within India, where uncertainty can stifle investment and lead to protracted legal battles.
The interplay between patent law and competition law has been a persistent challenge, as patent holders may sometimes be accused of leveraging exclusive rights in ways that raise competition concerns. A clear jurisdictional determination is essential for predictable market operations and will provide much-needed clarity to the intersection of intellectual property and antitrust enforcement in India.